Takeda to present four company-sponsored abstracts at the 15^th Annual Congress of the European Association for Haemophilia and Allied Disorders 2022

At this year’s virtual European Association for Haemophilia and Allied Disorders (EAHAD) congress (Feb. 2-4, 2022), we are sharing four abstracts. Abstracts posters: PO050, PO045, PO105 and PO120 can be found here.

Highlights of data to be presented include:

Abstract Poster Number

Title

Presenting Author

HEMOPHILIA A

Abstract PO050

Efficacy and Safety of Rurioctocog Alfa Pegol in Perioperative Management: Interim Results from An Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia A

Flora Peyvandi

Abstract PO045

Clinical Outcomes Following Prophylaxis with Rurioctocog Alfa Pegol in Patients with Hemophilia A: Real World Observational Data from the AHEAD International Study

Margareth Ozelo

Abstract PO105

Pharmacokinetic-Guided Prophylaxis with Recombinant Antihemophilic Factor Improves Bleeding Rates in Patients with Moderate Hemophilia: Real-World Observational Data from the AHEAD German Study

Robert Klamroth

ACQUIRED HEMOPHILIA A

Abstract PO120

Safety And Effectiveness Of Recombinant B-Domain–Deleted Porcine-Sequence Factor Viii For Acquired Hemophilia A In A Real-World Setting

Wolfgang Miesbach

Takeda to present four company-sponsored abstracts at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders 2022

HEMOPHILIA A

ACQUIRED HEMOPHILIA A

Takeda to present four company-sponsored abstracts at the 15^th Annual Congress of the European Association for Haemophilia and Allied Disorders 2022